X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SHASUN PHARMA ELDER PHARMA/
SHASUN PHARMA
 
P/E (TTM) x -0.2 123.9 - View Chart
P/BV x 0.1 8.5 1.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ELDER PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SHASUN PHARMA
Mar-14
ELDER PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs38094 403.4%   
Low Rs18846 412.3%   
Sales per share (Unadj.) Rs491.2214.2 229.3%  
Earnings per share (Unadj.) Rs-3.25.3 -59.6%  
Cash flow per share (Unadj.) Rs14.415.8 91.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs376.553.3 705.8%  
Shares outstanding (eoy) m20.5456.62 36.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.60.3 177.2%   
Avg P/E ratio x-89.313.1 -681.4%  
P/CF ratio (eoy) x19.74.4 446.1%  
Price / Book Value ratio x0.81.3 57.6%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m5,8333,958 147.4%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1792,164 100.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,08912,127 83.2%  
Other income Rs m257229 111.9%   
Total revenues Rs m10,34612,356 83.7%   
Gross profit Rs m-7921,009 -78.5%  
Depreciation Rs m361594 60.9%   
Interest Rs m2,756415 664.0%   
Profit before tax Rs m-3,653230 -1,590.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125-73 -172.1%   
Profit after tax Rs m-65302 -21.6%  
Gross profit margin %-7.88.3 -94.3%  
Effective tax rate %-3.4-31.7 10.8%   
Net profit margin %-0.62.5 -26.0%  
BALANCE SHEET DATA
Current assets Rs m9,2406,884 134.2%   
Current liabilities Rs m9,9988,456 118.2%   
Net working cap to sales %-7.5-13.0 57.9%  
Current ratio x0.90.8 113.5%  
Inventory Days Days4662 75.1%  
Debtors Days Days60108 55.7%  
Net fixed assets Rs m10,1244,970 203.7%   
Share capital Rs m206113 181.6%   
"Free" reserves Rs m5,5822,875 194.2%   
Net worth Rs m7,7343,020 256.1%   
Long term debt Rs m4,8891,817 269.0%   
Total assets Rs m22,88213,347 171.4%  
Interest coverage x-0.31.6 -20.9%   
Debt to equity ratio x0.60.6 105.1%  
Sales to assets ratio x0.40.9 48.5%   
Return on assets %11.85.4 218.8%  
Return on equity %-0.810.0 -8.4%  
Return on capital %22.313.3 167.5%  
Exports to sales %3.046.4 6.6%   
Imports to sales %0.414.2 3.0%   
Exports (fob) Rs m3075,622 5.5%   
Imports (cif) Rs m431,728 2.5%   
Fx inflow Rs m3075,843 5.2%   
Fx outflow Rs m1252,173 5.8%   
Net fx Rs m1813,669 4.9%   
CASH FLOW
From Operations Rs m11,754398 2,956.3%  
From Investments Rs m-561-1,635 34.3%  
From Financial Activity Rs m-6,7621,309 -516.7%  
Net Cashflow Rs m4,43271 6,224.3%  

Share Holding

Indian Promoters % 39.6 39.2 101.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 3.6 208.3%  
FIIs % 16.8 17.6 95.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 39.6 91.2%  
Shareholders   16,479 20,750 79.4%  
Pledged promoter(s) holding % 77.6 12.3 631.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare ELDER PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS